HK
Hikma Pharmaceuticals PLC
HKMPY · OTC
$41.31 +0.00% (+$0.00)
1M -7.38%
Market Cap $4.32B
P/E Ratio 10.71x
Div. Yield 4.16%
ROE 16.18%
Bulios Fair Price
$39.74
3.8% downside
Current Price
$41.31
Undervalued Fair Value Overvalued
According to Bulios Fair Price, HKMPY is currently trading close to its fair value. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
86 /100
Cheap P/E 10.71x
EV/EBITDA 6.73x
PEG 0.88x
Growth
60 /100
Stable EPS growth 29.16%
Rev. growth 10.07%
Book val. growth 6.69%
Profitability
65 /100
Moderate Gross margin 40.04%
Net margin 12.00%
FCF margin 4.84%
Quality
65 /100
Average ROIC 11.32%
ROE 16.18%
Asset turnover 0.59x
Debt
74 /100
Low Debt/Equity 0.64x
Current ratio 1.82x
Net debt/EBITDA 1.58x
Stability
83 /100
Stable Beta 0.66x
Rev. volatility 3.63%
Profitable years 6
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about HKMPY
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Said Samih Taleb Darwazah
Employees
9,400
Headquarters
London